Development of an NGS risk classifier in adult and pediatric cohort of patients with T-ALL. CR1-INT, CR1 intermediate risk; EOI, end of induction. Professional illustration by Patrick Lane, ScEYEnce Studios; the graph is reproduced from Figure 4B in the article by Simonin et al that begins on page 1... More about this image found in Development of an NGS risk classifier in adult and pediatric cohort of pati...

Figure 1. Integrative comutation patterns in MDS and implications for genotype-phenotype analysis. (A) Proportion and number of patients with or without gene mutations (mut.), cytogenetic alterations, and cnLOH events. (B) Number of patients with cnLOH at the most recurrent loci and co-occurrenc... More about this image found in Integrative comutation patterns in MDS and implications for genotype-phenot...

Figure 2. Derivation of 16 MDS molecular groups. (A) Schematic of the analytical workflow to identify molecular groups. Features were based on the presence or absence of genetic alterations (gene mutations, cytogenetic, and cnLOH events). Distinct allelic states or hot spots were also included b... More about this image found in Derivation of 16 MDS molecular groups. (A) Schematic of the analytical wor...

Figure 3. Molecular composition and main characteristics of MDS molecular groups. Each row represents a molecular subgroup, and molecular features are ordered by blocks of gene mutations, chromosomal losses, gains, rearrangements, and cnLOH events. For each subgroup, the relative proportions of ... More about this image found in Molecular composition and main characteristics of MDS molecular groups. Ea...

Figure 4. More about this image found in Untitled image

Associations between MDS molecular groups, clinical phenotypes, and outcomes. (A) Association between molecular groups and clinical phenotypes. Darker blue indicates co-occurrence, and darker red indicates mutual exclusivity. (B) Association between molecular groups and outcomes, for OS (left) and ... More about this image found in Associations between MDS molecular groups, clinical phenotypes, and outcome...

Figure 5. More about this image found in Untitled image

Genetic heterogeneity of s/t-MDS. (A) Prevalence of molecular groups in 267 patients with s/t-MDS. (B) Proportion of primary (red) and s/t-MDS (blue) within each molecular group and comparison with the full cohort (top). (C) Distribution of the number of mutated genes per patient in primary or s/t-... More about this image found in Genetic heterogeneity of s/t-MDS. (A) Prevalence of molecular groups in 26...

Figure 6. Genetic heterogeneity of MDS/MPN with ubiquitous RAS pathway mutations enrichment. (A) Prevalence of molecular groups in 536 patients with MDS/MPN color-coded by specific subtypes. The bi-TET2 group accounted for 33% of MDS/MPN cases and 42% (168/399) of CMML cases. The EZH2-ASXL1... More about this image found in Genetic heterogeneity of MDS/MPN with ubiquitous RAS pathway mutations en...